إدارة نوبات النقرس المتكررة عند وجود موانع لجميع العلاجات المعيارية: الكولشيسين والمضادات غير الستيرويدية للالتهاب والكورتيكوستيرويدات

References

DOI: 10.1136/annrheumdis-2016-209707

1. In patients with frequent flares and contraindications to colchicine, NSAIDs and corticosteroid (oral and injectable), IL-1 blockers should be considered for treating flares.
2. Current infection is a contraindication to the use of IL-1 blockers.
3. Two RCTs have reported that the anti-IL-1β monoclonal antibody canakinumab (150 mg subcutaneously, one dose) was superior to triamcinolone acetonide (40 mg subcutaneously, one dose) in reducing pain in patients with flare with contraindication, intolerance of or non-response to NSAIDs and/or colchicine.
4. A case series also suggest that this IL-1 receptor antagonist, administered subcutaneously at 100 mg for 3 days, could be effective in reducing pain in patients with acute attacks.